Collagenase clostridium histolyticum intralesional injections for the treatment of Peyronie's disease: a safety profile

Affiliations

Editorial

Sylvia Yan et al. Transl Androl Urol. 2017 Feb.

. 2017 Feb;6(1):123-126.

doi: 10.21037/tau.2016.12.08.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease.
Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Yafi FA, et al. J Sex Med. 2016 Apr;13(4):684-9. doi: 10.1016/j.jsxm.2016.02.105. Epub 2016 Mar 25. J Sex Med. 2016. PMID: 27045265

1. Joice GA, Burnett AL. Nonsurgical Interventions for Peyronie's Disease: Update as of 2016. World J Mens Health 2016;34:65-72. 10.5534/wjmh.2016.34.2.65 - DOI - PMC - PubMed
1. Yafi FA, Pinsky MR, Sangkum P, et al. Therapeutic advances in the treatment of Peyronie's disease. Andrology 2015;3:650-60. 10.1111/andr.12058 - DOI - PubMed
1. Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 Studies. The Journal of Urology 2013;190:199-207. 10.1016/j.juro.2013.01.087 - DOI - PubMed
1. Gokce A, Wang JC, Powers MK, et al. Current and emerging treatment options for Peyronie's disease. Res Rep Urol 2013;5:17-27. - PMC - PubMed
1. Martínez-Salamanca JI, Egui A, Moncada I, et al. Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med 2014;11:506-15. 10.1111/jsm.12400 - DOI - PubMed